ClinConnect ClinConnect Logo
Search / Trial NCT06289348

Announcement of Rare Metabolic Diseases in Systematic Newborn Screening: the Phenylketonuria Experience.

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 26, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Presymptomatic Announcement Systematic Neonatal Screening Rare Diseases Genetic Disease Phenylketonuria Care Relationship Psychological Trauma Psychological Impact Parent Child Bonding Parenthood

ClinConnect Summary

This clinical trial is focused on studying the emotional and psychological effects of informing parents about a rare condition called Phenylketonuria (PKU), which is detected at birth through routine newborn screenings. The goal is to better understand how parents feel when they learn about their child's diagnosis and how healthcare providers can improve the way they communicate this important news. By examining the experiences of both parents and medical teams, the researchers hope to enhance the support given to families during this challenging time.

To be eligible for this study, participants must be parents or doctors of a child who has been screened for PKU and must be experiencing this diagnosis for the first time, meaning the child is the first in the family to be diagnosed with PKU. The study is not yet recruiting participants, but families who fit these criteria can expect to share their experiences in interviews that will help shape better practices for communicating difficult news in the future. It's important to note that families who do not speak French or have certain personal circumstances may not be able to participate.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Parent or doctor of a child screened for PKU, born during the inclusion phase of the study
  • Family's first exposure to PKU: the PKU child must be either the eldest or the first sibling to be diagnosed with PKU following neonatal screening
  • Exclusion Criteria:
  • Failure to master the French language.
  • Child screened is neither the eldest nor the first sibling to be screened.
  • Refusal by the parents.
  • Any other reason which, in the investigator's judgement, would impair the participants' ability to follow the study protocol, or the interpretation of interview data (e.g. the participating parent has a history of serious psychiatric pathology, one of the parents died at the child's birth, Couples in which one of the members suffers from a known decompensated psychiatric pathology at the time of recruitment. Couples where one of the members is under legal protection or a security measure, etc ...).

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Paris, , France

Patients applied

0 patients applied

Trial Officials

Céline BENSIMON

Study Chair

Assistance Publique - Hôpitaux de Paris

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported